Advertisement
UK markets open in 4 hours 58 minutes
  • NIKKEI 225

    39,611.07
    +437.92 (+1.12%)
     
  • HANG SENG

    18,048.29
    -24.61 (-0.14%)
     
  • CRUDE OIL

    80.92
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,324.00
    -6.80 (-0.29%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • Bitcoin GBP

    48,917.59
    +1,210.48 (+2.54%)
     
  • CMC Crypto 200

    1,286.06
    +36.94 (+2.96%)
     
  • NASDAQ Composite

    17,717.65
    +220.84 (+1.26%)
     
  • UK FTSE All Share

    4,493.07
    -21.69 (-0.48%)
     

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com